BioNTech SE (BNTX) – Exploring mRNA for continued growth

in , , on April 17, 2023

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

BioNTech SE (BNTX) Q4FY22

BioNTech is also seen buying back its share at this lower price. It expects that the stock will again increase as it plans to launch new drugs and vaccines using mRNA technology



– Enterprise Value
– CrispIdea Forecast
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Developments

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages: 27

To download the previous quarter’s equity report click here

Follow our LinkedIn page for more updates

Release Information

  • Price


  • Released

    April 17, 2023

  • Last Updated

    April 17, 2023